美国弥漫性大 B 细胞淋巴瘤和滤泡性淋巴瘤患者的经济负担。
Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA.
机构信息
Hematology/Oncology & Infectious Disease, Hennepin County Medical Center, University of Minnesota, 701 Park Ave Ste 310, Minneapolis, MN 55415, USA.
Millennium Pharmaceuticals Inc., (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), 40 Landsdowne St, Cambridge, MA 0213, USA.
出版信息
Future Oncol. 2018 Oct;14(25):2627-2642. doi: 10.2217/fon-2018-0267. Epub 2018 Jun 18.
AIM
Evaluate healthcare costs and utilization of treated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients.
MATERIALS & METHODS: Adults with newly diagnosed DLBCL and FL between 1 January 2008 and 31 October 2015 were identified in the Optum™ claims database. Healthcare costs and utilization were assessed from diagnosis date until end of follow-up.
RESULTS
A total of 1267 DLBCL- and 1595 FL-treated patients were identified. Mean per-patient, per-month cost during follow-up was US$11,890 for DLBCL and US$10,460 for FL. Healthcare costs and utilization decreased from year 1 to 2 following diagnosis, due to a decrease in chemotherapy services, inpatient admissions and other outpatient services.
CONCLUSION
The economic burden of treated DLBCL and FL is considerable, especially in the first year following diagnosis.
目的
评估治疗弥漫性大 B 细胞淋巴瘤（DLBCL）和滤泡性淋巴瘤（FL）患者的医疗保健费用和利用情况。
材料与方法
在 Optum™索赔数据库中，确定了 2008 年 1 月 1 日至 2015 年 10 月 31 日期间新诊断为 DLBCL 和 FL 的成年人。从诊断日期到随访结束，评估医疗保健费用和利用情况。
结果
共确定了 1267 例 DLBCL 治疗患者和 1595 例 FL 治疗患者。在随访期间，每位患者每月的平均医疗费用为 DLBCL 患者 11890 美元，FL 患者 10460 美元。由于化疗服务、住院和其他门诊服务的减少，诊断后第 1 年至第 2 年，医疗保健费用和利用情况有所下降。
结论
治疗后的 DLBCL 和 FL 的经济负担相当大，尤其是在诊断后的第一年。
Zotero 插件